Molecular biomarkers in a representative sample of Colombian patients with colorectal cancer studied at Fundación Santa Fe de Bogotá

microRNAs (miRNAs) have been proposed as promising molecular biomarkers for diagnosis, prognosis, and responsive therapeutic targets in different types of cancer, including colorectal cancer (CRC). In this study, we evaluated the expression levels of 84 cancer-associated miRNAs in a cohort of 39 human samples comprising 13 peritumoral and 26 tumoral tissues from surgical specimens of CRC patients. KRAS mutations were detected in 11 tumoral samples. In a first analysis, we found 5 miRNAs (miR-215-5p, miR-9-5p, miR-138-5p, miR378a-3p, and miR-150-5p) that were significantly downregulated and one upregulated (miR-135b-5p) in tumoral tissues compared with the peritumoral tissues. Furthermore, by comparing miRNA profile between KRAS mutated CRC tissues respect to wild type CRC tissues, we found 7 miRNA (miR-27b-3p, miR-191-5p, miR-let7d-5p, miR-15b-5p, miR-98-5p, miR-10a-5p, and miR-149-5p) downregulated in KRAS mutated condition. In conclusion, we have identified a panel of miRNAs that specifically distinguish CRC tissues from peritumoral tissue and a different set of miRNAs specific for CRC with KRAS mutations. These findings may contribute to the discovering of new molecular biomarkers with clinic relevance and might shed light on novel molecular aspects of CRC.

Download Full-text

Geographic disparities in cancer screening and fatalism among a nationally representative sample of US adults

Journal of Epidemiology & Community Health ◽

10.1136/jech-2019-212425 ◽

2019 ◽

Vol 73 (12) ◽

pp. 1128-1135

Author(s):

Jennifer L Moss ◽

Rebecca Ehrenkranz ◽

Lilian G Perez ◽

Brionna Y Hair ◽

Anne K Julian

Keyword(s):

Breast Cancer ◽

Colorectal Cancer ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Colorectal Cancer Screening ◽

Rural Areas ◽

Representative Sample ◽

Racial Segregation ◽

Cancer Fatalism ◽

Nationally Representative

BackgroundCancer screening in the USA is suboptimal, particularly for individuals living in vulnerable communities. This study aimed to understand how rurality and racial segregation are independently and interactively associated with cancer screening and cancer fatalism.MethodsWe used data from a nationally representative sample of adults (n=17 736) from National Cancer Institute’s Health Information National Trends Survey, 2011–2017, including cancer screening (colorectal, breast, cervical, prostate) among eligible participants and cancer fatalism. These data were linked to county-level metropolitan status/rurality (US Department of Agriculture) and racial segregation (US Census). We conducted multivariable analyses of associations of geographic variables with screening and fatalism.ResultsBreast cancer screening was lower in rural (92%, SE=1.5%) than urban counties (96%, SE=0.5%) (adjusted OR (aOR)=0.52, 95% CI 0.31 to 0.87). Colorectal cancer screening was higher in highly segregated (70%, SE=1.0%) than less segregated counties (65%, SE=1.7%) (aOR=1.28, 95% CI 1.04 to 1.58). Remaining outcomes did not vary by rurality or segregation, and these variables did not interact in their associations with screening or fatalism.ConclusionSimilar to previous studies, breast cancer screening was less common in rural areas. Contrary to expectations, colorectal cancer screening was higher in highly segregated counties. More research is needed on the influence of geography on cancer screening and beliefs, and how access to facilities or information may mediate these relationships.

Download Full-text

153P Novel, highly sensitive molecular biomarkers for metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdv523.14 ◽

2015 ◽

Vol 26 ◽

pp. ix42

Author(s):

G. Takahashi ◽

T. Yamada ◽

H. Kan ◽

S. Matsumoto ◽

M. Koizumi ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Molecular Biomarkers ◽

Highly Sensitive

Download Full-text

Abstract LB-354: Investigating potential molecular biomarkers for cetuximab response in metastatic colorectal cancer tissue using reverse phase protein array

10.1158/1538-7445.am2016-lb-354 ◽

2016 ◽

Author(s):

Naser Monsefi ◽

Robert O’Byrne ◽

Steven Carberry ◽

Eugenia R. Zanella ◽

Ana Barat ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Molecular Biomarkers ◽

Protein Array ◽

Cancer Tissue ◽

Reverse Phase Protein Array ◽

Reverse Phase ◽

Colorectal Cancer Tissue ◽

Phase Protein

Download Full-text

Impact of organization of colorectal cancer screening: Results of EDIFICE study

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.6078 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 6078-6078

Author(s):

Y. Coscas ◽

D. Serin ◽

L. Cals ◽

F. Eisinger ◽

J. Blay ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Screening ◽

Colorectal Cancer Screening ◽

Representative Sample ◽

Consensus Conference ◽

Demographic Characteristics ◽

Self Report ◽

Nationwide Observational Study ◽

Colorectal Screening ◽

Second Wave

6078 Background: The EDIFICE study aimed to allow better understanding of population’s adhesion to the tests available for the 4 most frequent cancers: breast, colorectal, prostate and lung. In 1998 the French National Consensus Conference advocated for mass cancer screening (CS) using Hemoccult II. The departments are divided according to the existence or not of an organized program: this screening was organized in 22 departments (3 “scout” started in 1998, 9 “first wave” in 2003 and 12 “second wave” in 2004). Results are reported hereunder. Methods: This first nationwide observational study was carried out in France from January 18th to February 2nd, 2005 among a representative sample of 1504 subjects aged between 40 and 75 years and a representative sample of 600 general practitioners (GPs). Information about participating subjects included socio-demographic characteristics, attitude towards CS, and about GPs’ medical practice regarding CS. Results: Only 25% of the 970 subjects aged between 50 and 74 years had undergone a colorectal screening test. In the organized departments (OD), the rate of persons who self-report any colorectal cancer screening was 34% vs 20% in unorganized departments (UD) (OR=1.99, CI95% 1.47- 2.69, p<0.001). The rate of recent screening within a range of 2 years was 24% for OD vs 8% for UD (OR=3.35, CI95% 1.91- 5.88, p<0.01). The rate of “fear of the test and/or its results” was higher in OD: 11% versus 6% (OR=1.97, CI95% 1.11–3.49). The rate of GPs who advocated systematically for screening was 40%, 29%, 26% and 13% for scout, first wave, second wave OD and baseline UD respectively. Organization reduced the rate of screening based on colonoscopy alone from 69% persons in UD to 35% in the OD. Conclusions: The main result of this survey comparing data in the same frame of time, in the same country, is that organized programs for colorectal cancer impact of health outcomes. No significant financial relationships to disclose.

Download Full-text